Trevena Announces Wake Forest Baptist Health Joining OLINVYK® Clinical Outcomes Study
-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive...
Month: August 2021
Jushi Holdings Inc. Reports Second Quarter 2021 Financial Results
Second Quarter 2021 Revenue Increases 14.6% to $47.7 million as Compared to the First Quarter 2021 Net Income of $4.8...
Silence Therapeutics to Participate in September Investor Conferences
Silence Therapeutics to Participate in September Investor Conferences 25 August 2021 LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN...
Helius Medical Technologies, Inc. Announces Voluntary De-Listing from Toronto Stock Exchange
NEWTOWN, Pa., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech...
Jushi Holdings Inc. to Open Its 21st BEYOND / HELLO™ Retail Location Nationwide, 14th Store in Pennsylvania and Third in the City of Philadelphia Through its Subsidiary Agape Total Health Care Inc
BEYOND / HELLO™ University City to Begin Serving Medical Marijuana Patients in the Culturally Diverse Academic Epicenter of Philadelphia on...
Recruitment of the smallest infants in the Connection study paused
IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today,...
Emergent BioSolutions’ COVID-19 Human Immune Globulin Product Candidate to be Evaluated in NIH-Sponsored Phase 3 Clinical Trial (INSIGHT-012) of Hyperimmune Intravenous Immunoglobulin for Outpatient Treatment of COVID-19
NIAID has initiated a Phase 3 clinical trial to evaluate the efficacy and safety of hyperimmune globulin products, including Emergent’s...
Cassava Sciences Responds to Allegations
AUSTIN, Texas, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease,...
Canadians Urged to Take Action for MS
MS Society of Canada’s campaign to inform federal candidates of priorities important to the multiple sclerosis community is under wayTORONTO,...
CellMax Life Earns FDA Breakthrough Device Designation for Colon Cancer & Pre-Cancerous Adenomas Screening Blood Test
FirstSight™ Now Qualifies for Expedited FDA Review Process as a Blood Test for Detection of Advanced Neoplasia (Colorectal Cancer &...
BBS-Bioactive Bone Substitutes Plc: Half-Year Report January 1st –June 30th 2021 (Unaudited)
BBS-Bioactive Bone Substitutes Plc’s Company Release August 25th 12.45 p.m. January-June 2021 shortly (comparison period 1-6/2020) Company’s operations have grown...
Orion Corporation: Managers’ transactions – Kari Jussi Aho
ORION CORPORATION MANAGERS’ TRANSACTIONS 25 AUGUST 2021 at 12.00 EEST Orion Corporation: Managers’ transactions – Kari Jussi Aho Orion...
Bavarian Nordic Announces First Half 2021 Results
COPENHAGEN, Denmark, August 25, 2021 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress...
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
Validation initiates formal evaluation of application which started on August 19, 2021; decision expected mid-2022If approved, efgartigimod will be the...
IBA Reports Half Year 2021 Results
25% SALES GROWTH AND STRONG IMPROVEMENT IN REBIT LINKED TO INCREASED ACTIVITY AND ACCELERATED BACKLOG CONVERSION STRONG BALANCE SHEET WITH...
HEXO Corp. Closes US$144.8 Million Underwritten Public Offering
OTTAWA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- HEXO Corp (“HEXO” or the “Company”) (TSX: HEXO; NASDAQ: HEXO) today announced the...
VitalHub Increases Q2 2021 Revenue to $5.8M While Continuing to Improve on Financial Metrics Across the Business
TORONTO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) announced today it has filed...
ACR Webinar: Reproductive Health & Rheumatic Disease
Atlanta, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Rheumatic diseases are lifelong conditions that affect over 54 million Americans, often during...
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer Webinar on Wednesday, September 1st @ 10am ET/4pm CET...
Progenity Announces Closing of $40 Million Underwritten Public Offering
SAN DIEGO, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Progenity, Inc. (“Progenity”) (Nasdaq: PROG), an innovative biotechnology company, today announced the...
